Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes

Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment


      Oxidized low-density lipoprotein (oxLDL) is immunogenic while oxidized phospholipids (oxPL) formed on oxLDL and lysophosphatidylcholine (lyso-PC) generated during LDL oxidation through the hydrolysis of oxPL by the lipoprotein-associated phospholipase A2 (Lp-PLA2), significantly contribute to oxLDL immunogenicity. We determined the autoantibody titers against various forms of mildly oxLDL in patients with acute coronary syndromes without persistent elevation of the ST segment (NSTE-ACS) and with undetectable serum levels of lipoprotein (a). Moreover, the effect of early atorvastatin administration on these autoantibody titers was evaluated. From the 133 consecutive NSTE-ACS patients, 55 were eligible for the study. Thirty-four received atorvastatin (group A), whereas 21 did not received any hypolipdemic therapy (group B). Two forms of copper-oxidized LDL were prepared at the end of propagation or decomposition phase (oxLDLP or oxLDLD, respectively). Similar types of oxLDL were prepared after previous inactivation of the endogenous Lp-PLA2 [oxLDL(−)]. In group B, autoantibody titers of IgG class against oxLDLP and oxLDLD were elevated at 1 month of follow-up to reach the baseline values 3 months afterwards. By contrast the titers against oxLDL(−)P and oxLDL(−)D increased at 1 month of follow-up and remained elevated for up to 6 months of follow-up. Atorvastatin treatment prevented the elevation of autoantibody titers against all forms of oxidized LDL. We conclude that a short-term immune response against oxLDLP and oxLDLD (enriched in lyso-PC) and a chronic immune response against oxLDL(−)P and oxLDL(−)D (enriched in oxPL) are observed after an NSTE-ACS, suggesting an important role of the LDL-associated Lp-PLA2 in modulating these immune responses. Early atorvastatin treatment prevents both immune responses; however, the clinical significance of this effect remains to be established.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Navab M.
        • Ananthramaiah G.M.
        • Reddy S.T.
        • et al.
        The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL.
        J Lipid Res. 2004; 45: 993-1007
        • Itabe H.
        Oxidized low-density lipoproteins: what is understood and what remains to be clarified.
        Biol Pharm Bull. 2003; 26: 1-9
        • Esterbauer H.
        • Gebicki J.
        • Puhl H.
        • Jurgens G.
        The role of lipid peroxidation and antioxidants in oxidative modification of LDL.
        Free Radic Biol Med. 1992; 13: 341-390
        • Wu R.
        • Huang Y.H.
        • Elinder L.S.
        • Frostegard J.
        Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL.
        Arterioscler Thromb Vasc Biol. 1998; 18: 626-630
        • Palinski W.
        • Witztum J.L.
        Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis.
        J Intern Med. 2000; 247: 371-380
        • Tselepis A.D.
        • Chapman J.M.
        Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
        Atheroscler Suppl. 2002; 3: 57-68
        • Lourida E.S.
        • Papathanasiou A.
        • Goudevenos J.
        • Tselepis A.D.
        The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease.
        Prostag Leukot Essent Fatty Acids. 2006; 75: 117-126
        • Edelstein C.
        • Pfaffinger D.
        • Hinman J.
        • et al.
        Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a).
        J Biol Chem. 2003; 278: 52841-52847
        • Tsouli S.G.
        • Kiortsis D.N.
        • Lourida E.S.
        • et al.
        Autoantibody titers against OxLDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia.
        J Lipid Res. 2006; 47: 2208-2214
        • Ehara S.
        • Ueda M.
        • Naruko T.
        • et al.
        Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes.
        Circulation. 2001; 103: 1955-1960
        • Holvoet P.
        • Collen D.
        • Van-de-Werf F.
        Malondialdehyde-modified LDL as a marker of acute coronary syndromes.
        JAMA. 1999; 281: 1718-1721
        • Tsimikas S.
        • Bergmark C.
        • Beyer R.
        • et al.
        Temporal increases in plasma markers of oxidized low-density liporpotein strongly reflect the presence of acute coronary syndromes.
        J Am Coll Cardiol. 2003; 41: 360-370
        • Liapikos Th.
        • Antonopoulou S.
        • Karabina S.-A.
        • Tsoukatos D.C.
        • Demopoulos C.A.
        • Tselepis A.D.
        Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated.
        Biochem Biophys Acta. 1994; 1212: 353-360
        • Dentan C.
        • Lesnik P.
        • Chapman M.J.
        • Ninio E.
        PAF-acether-degrading acetylhydrolase in plasma LDL is inactivated by copper- and cell-mediated oxidation.
        Arterioscler Thromb. 1994; 14: 353-360
        • Tsimikas S.
        • Brilakis E.S.
        • Miller E.R.
        • et al.
        Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.
        N Engl J Med. 2005; 353: 46-57
        • Tsimikas S.
        • Lau H.
        • Han S.
        • et al.
        Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a).
        Circulation. 2004; 109: 3164-3170
        • Braunwald E.
        • Antman E.M.
        • Beasley J.W.
        • et al.
        ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina).
        J Am Coll Cardiol. 2002; 40: 1366-1374
        • Dentan C.
        • Tselepis A.D.
        • Chapman M.
        • Ninio E.
        Pefabloc 4-[2-Aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase.
        Biochim Biophys Acta. 1996; 1299: 353-357
        • Karabina S.-A.
        • Liapikos Th
        • Grekas G.
        • Goudevenos J.
        • Tselepis A.D.
        Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein.
        Biochim Biophys Acta. 1994; 1213: 34-38
        • Tsimihodimos V.
        • Karabina S.-A.
        • Tambaki A.
        • et al.
        Altered distribution of PAF-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia.
        J Lipid Res. 2002; 43: 256-263
        • Inoue T.
        • Uchida T.
        • Kamishirado H.
        • Takayanagi K.
        • Morooka S.
        Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease.
        J Am Coll Cardiol. 2001; 37: 1871-1876
        • Tsimikas S.
        • Witztum J.L.
        Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk.
        Circulation. 2001; 103: 1930-1932
        • Inoue T.
        • Uchida T.
        • Kamishirado H.
        • Takayanagi K.
        • Hayashi T.
        • Morroka S.
        Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease.
        J Am Coll Cardiol. 2001; 37: 775-779
        • Tsimikas S.
        • Witztum J.L.
        • Miller E.R.
        • et al.
        High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
        Circulation. 2004; 110: 1406-1412
        • van Tits L.J.H.
        • van Himebergen T.M.
        • Lemmers H.L.M.
        • de Graaf J.
        • Stalenhoef A.F.H.
        Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia.
        Atherosclerosis. 2006; 185: 1307-1312
        • Aviram M.
        • Rosenblat M.
        • Bisgaier C.L.
        Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation.
        Atherosclerosis. 1998; 138: 271-280
      1. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.
        Eur Heart J. 2001; 22: 554-572
        • Pitsavos C.
        • Panagiotakos D.B.
        • Antonoulas A.
        • et al.
        Epidemiology of acute coronary syndromes in a Mediterranean country; aims, design and baseline characteristics of the Greek study of acute coronary syndromes (GREECS).
        BMC Public Health. 2005; 5: 23